10 Mar COVID Trial Networks Pivot to Studying Flu

By Kristina Fiore, Megpage Today

This story is a sidebar to a main story about findings from the earliest clinical trials launched during the COVID pandemic. To read the full story, click here.

Clinical trial networks developed during the COVID-19 pandemic are now being leveraged to study treatments for other respiratory diseases, including influenza.

Both the U.S. ACTIV program and the U.K. RECOVERY program have pivoted, in part with the goal of keeping the networks active should another pandemic occur.

“It was so laborious to put together, not only the networks within the U.S., but globally,” said Stacey Adam, PhD, a vice president of science partnerships at the Foundation for the National Institutes of Health, which managed the ACTIV portfolio. Read more…